276 related articles for article (PubMed ID: 20136921)
21. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
Davies A; Cifaldi MA; Segurado OG; Weisman MH
J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363
[TBL] [Abstract][Full Text] [Related]
22. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation.
Martyn-Simmons CL; Green L; Ash G; Groves RW; Smith CH; Barker JN
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1394-7. PubMed ID: 19573024
[TBL] [Abstract][Full Text] [Related]
23. Impact of TNF-α antagonists on the quality of life in selected skin diseases.
Gisondi P; Girolomoni G
G Ital Dermatol Venereol; 2013 Jun; 148(3):243-8. PubMed ID: 23670060
[TBL] [Abstract][Full Text] [Related]
24. [Analysis of the cost effectiveness of home-based phototherapy with narrow-band UV-B radiation compared with biological drugs for the treatment of moderate to severe psoriasis].
Vañó-Galván S; Gárate MT; Fleta-Asín B; Hidalgo A; Fernández-Guarino M; Bermejo T; Jaén P
Actas Dermosifiliogr; 2012 Mar; 103(2):127-37. PubMed ID: 22036021
[TBL] [Abstract][Full Text] [Related]
25. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R; Kragballe K; Dam TN; Skov L
Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
[TBL] [Abstract][Full Text] [Related]
26. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
[TBL] [Abstract][Full Text] [Related]
27. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
Langley RG
J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
[TBL] [Abstract][Full Text] [Related]
28. Anti-TNF agents for the treatment of psoriasis.
Kircik LH; Del Rosso JQ
J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
[TBL] [Abstract][Full Text] [Related]
29. Biological treatments for moderate-to-severe psoriasis: indirect comparison.
Galván-Banqueri M; Marín Gil R; Santos Ramos B; Bautista Paloma FJ
J Clin Pharm Ther; 2013 Apr; 38(2):121-30. PubMed ID: 23442134
[TBL] [Abstract][Full Text] [Related]
30. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
31. Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system.
Wang SH; Chi CC; Hu S
Int J Dermatol; 2014 Sep; 53(9):1151-6. PubMed ID: 24738910
[TBL] [Abstract][Full Text] [Related]
32. Tumor necrosis factor antagonists in the therapy of psoriasis.
Mössner R; Schön MP; Reich K
Clin Dermatol; 2008; 26(5):486-502. PubMed ID: 18755367
[TBL] [Abstract][Full Text] [Related]
33. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis.
Bansback N; Sizto S; Sun H; Feldman S; Willian MK; Anis A
Dermatology; 2009; 219(3):209-18. PubMed ID: 19657180
[TBL] [Abstract][Full Text] [Related]
35. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
36. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
37. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.
Boonen A; van der Heijde D; Severens JL; Boendermaker A; Landewé R; Braun J; Brandt J; Sieper J; van der Linden S
Ann Rheum Dis; 2006 Feb; 65(2):201-8. PubMed ID: 16014677
[TBL] [Abstract][Full Text] [Related]
38. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
[TBL] [Abstract][Full Text] [Related]
39. TNF-alpha inhibitors in dermatology.
Cordoro KM; Feldman SR
Skin Therapy Lett; 2007 Sep; 12(7):4-6. PubMed ID: 17940711
[TBL] [Abstract][Full Text] [Related]
40. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
